Cyclacel Pharmaceuticals Inc [CYCC] stock prices are up 14.79% to $0.41 at the moment. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The CYCC shares have gain 11.38% over the last week, with a monthly amount drifted -82.24%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
On September 07, 2018, Ladenburg Thalmann initiated with a Buy rating. H.C. Wainwright started tracking the stock assigning a Buy rating and suggested a price target of $5 on October 16, 2015. Roth Capital initiated its recommendation with a Buy and recommended $7 as its price target on February 04, 2010. In a note dated August 12, 2008, Piper Jaffray initiated an Buy rating and provided a target price of $5 on this stock.
The stock price of Cyclacel Pharmaceuticals Inc [CYCC] has been fluctuating between $0.25 and $39.84 over the past year. Currently, Wall Street analysts expect the stock to reach $1 within the next 12 months. Cyclacel Pharmaceuticals Inc [NASDAQ: CYCC] shares were valued at $0.41 at the most recent close of the market. An investor can expect a potential return of 143.9% based on the average CYCC price forecast.
Analyzing the CYCC fundamentals
The Cyclacel Pharmaceuticals Inc [NASDAQ:CYCC] reported sales of 0.01M for trailing twelve months, representing a drop of -100.00%. Gross Profit Margin for this corporation currently stands at 1.29% with Operating Profit Margin at 604.05%, Pretax Profit Margin comes in at 370.24%, and Net Profit Margin reading is 397.48%. To continue investigating profitability, this company’s Return on Assets is posted at -2.24, Equity is -36.41 and Total Capital is -4.13. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.3353 points at the first support level, and at 0.2586 for the second support level. However, for the 1st resistance point, the stock is sitting at 0.4765, and for the 2nd resistance point, it is at 0.5410.
Ratios To Look Out For
It’s worth pointing out that Cyclacel Pharmaceuticals Inc [NASDAQ:CYCC]’s Current Ratio is 5.60. Also, the Quick Ratio is 5.60, while the Cash Ratio stands at 5.2. Considering the valuation of this stock, the price to sales ratio is 918.00, the price to book ratio is 1.74.
Transactions by insiders
Recent insider trading involved Lazar David E., Interim CEO, that happened on Feb 26 ’25 when 194.63 million shares were sold.
